Highlight
- Most patients with newly diagnosed focal epilepsy continue to experience seizures for at least one year after starting antiseizure medication (ASM) therapy.
- About 23% of patients develop treatment resistance within the first year, as defined by failure to respond to two adequate ASM trials.
- Median time to seizure freedom is approximately 12 months, indicating a prolonged adjustment period necessary for optimal seizure control.
- Prognostic factors for resistance include a history of psychiatric disorders and high pretreatment seizure frequency.
Study Background and Disease Burden
Focal epilepsy, characterized by seizures originating from a specific region of the brain, accounts for approximately 60% of all epilepsy cases worldwide. Despite advances in antiseizure medications (ASMs), substantial proportions of patients continue to experience seizures, leading to impaired quality of life, psychological distress, and increased healthcare utilization. Optimizing seizure control early in treatment is critical for mitigating these adverse outcomes and reducing the risk of long-term complications, such as injury and sudden unexpected death in epilepsy (SUDEP). However, the temporal dynamics of treatment response and the predictors of resistance in focal epilepsy remain incompletely understood. The recent analysis from the Human Epilepsy Project (HEP) addresses this gap by providing prospective data on seizure outcomes following initiation of ASM therapy in newly diagnosed focal epilepsy cases.
Study Design
The HEP analysis prospectively enrolled 448 patients aged 12 to 60 years with newly diagnosed focal epilepsy across 34 epilepsy centers in North America, Europe, and Australia. Participants were recruited within four months of beginning ASM therapy and were followed longitudinally for a median duration of three years. The median age at treatment initiation was 32 years, and 60% of participants were female. The primary outcome was seizure freedom, defined as the absence of seizures, and secondary outcomes included the development of treatment resistance—defined as failure of two appropriately chosen and tolerated ASM regimens. The study also explored potential clinical predictors of treatment resistance and timing of seizure remission.
Key Findings
At the conclusion of the follow-up period, approximately 60% of participants achieved seizure freedom, whereas 23% developed treatment resistance. The median time to seizure freedom was 12.1 months, indicating that for many patients, seizure control is often not achieved in the first several months following ASM initiation. Patients who attained seizure freedom without relapse did so relatively rapidly (median, 2.2 months), whereas those experiencing early relapse took longer to achieve control (median, 7.4 months). Notably, about half of the patients with treatment resistance were identified by 6 to 8 months into therapy.
Critically, more than two thirds of patients exhibited ongoing or worsening seizure activity during the first treatment year, underscoring a high seizure burden early in disease management. These data suggest clinicians and patients should anticipate a potentially prolonged and iterative treatment process rather than immediate seizure remission.
The choice of initial ASM also impacted outcomes. Levetiracetam was the most commonly prescribed first-line medication (57%). Despite its widespread usage owing to favorable drug interaction profiles and versatility across seizure types, only about 25% of patients achieved seizure freedom with levetiracetam monotherapy. Prior literature indicates that sodium channel blockers may demonstrate superior efficacy in some focal epilepsy populations, suggesting room for optimizing initial ASM selection.
Prognostic markers of treatment resistance included self-reported histories of depression, anxiety, or other psychiatric disorders, which nearly doubled the risk of resistance (relative risk 1.78). Additionally, higher baseline seizure frequency was associated with increased risk of resistance, while infrequent seizure history correlated with better responsiveness (relative risk 0.41). These findings highlight the interplay between neuropsychiatric comorbidity, seizure burden, and responsiveness to therapy.
The authors caution that persistence of seizures in the first year does not definitively predict eventual treatment failure, emphasizing the importance of careful clinical evaluation and treatment adjustments during this period. Early identification of ASM failure and switching to alternative or combination therapies, along with tailoring therapy to individual patient profiles, may improve long-term outcomes.
Expert Commentary
Dr. Jacqueline French, co-principal investigator of HEP and a respected authority in epilepsy care, noted that their findings reflect the real-world challenges many patients face, with a prolonged “adjustment period” to find an effective treatment regimen. This contrasts with the expectation for rapid seizure control often envisioned by patients and clinicians. The persistence of seizures despite newer ASMs indicates that while pharmacological options have expanded, their impact on overall prognosis remains limited. The study also highlights the necessity of integrating psychiatric assessment and seizure frequency into treatment planning to personalize seizure management.
While the study’s strength lies in its prospective multicenter design and sizeable cohort, limitations include reliance on self-reported psychiatric comorbidity and potential heterogeneity in ASM dosing regimens and adherence across centers. The findings stress the ongoing need for biomarkers and tools to predict treatment response more accurately and for innovative therapies to address refractory focal epilepsy.
Conclusion
The Human Epilepsy Project’s recent analysis reveals that seizure control in focal epilepsy is often delayed beyond the first year of ASM treatment, with nearly one quarter of patients developing drug resistance early in therapy. This prolonged timeframe to seizure remission underlines the complex and individualized nature of epilepsy treatment. Clinicians should counsel patients to expect a dynamic treatment course with potential medication trials and adjustments. Early identification of therapeutic failure and consideration of alternative strategies are essential to optimize outcomes. The study also identifies psychiatric comorbidities and seizure frequency as important prognostic factors, underscoring the need for comprehensive patient evaluation. Continued research into personalized medicine approaches and novel therapeutic options remains critical to improve prognosis in focal epilepsy.
